Infectious Diseases

Collectively, Tmunity’s scientific founders have more than 20 years of experience in HIV clinical studies, including adoptive transfer of retroviral-modified CD4-CD3 CAR-T cells and first-in-human studies of lentiviral vectors and zinc finger nucleases.


Tmunity is leveraging this expertise to apply multiple strategies to the creation of HIV-specific and HIV-resistant T cells that could make the immune system “HIV-proof” by making it impossible for HIV to escape. These approaches include:


  • Repopulating T cell compartments with HIV-resistant and HIV-specific immunity

  • Targeting HIV [Env] with genetically modified autologous T cells expressing optimized CD4-CAR

  • Protecting T cells from HIV infection by disrupting CCR5 or CXCR4 co-receptor expression

  • Activating HIV-1 reservoir with a latency reversal agent and measuring durable impact of engineered T cells


Tmunity is planning to initiate Phase 1 clinical studies in HIV in Q1 2018.

Legal  |  Privacy  |  Cookies

Tmunity Therapeutics Inc.
3020 Market Street, Suite 535
Philadelphia, PA 19104


+1 215 966 1600

© 2020 Tmunity Therapeutics. All rights reserved.